Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Thomas A. Szlosek net worth and biography

Thomas Szlosek Biography and Net Worth

CFO of Avantor

Thomas A. Szlosek is Avantor’s Executive Vice President and Chief Financial Officer. As CFO, Mr. Szlosek oversees: Accounting; Business Support; Financial Planning and Analysis; Treasury; M&A; Investor Relations; Internal Audit; and Tax Functions at Avantor. He joined Avantor in December 2018, prior to which he spent 14 years with Honeywell, including the last five years as Chief Financial Officer. Mr. Szlosek also spent eight years with GE Corporation, including three years as the CFO for GE Medical Systems, based in Asia, and two years as the CFO for GE Consumer Finance, based in Ireland. Mr. Szlosek currently serves on the board of directors of RXO as well as Janus International Group where he chairs the Audit Committee for each. He is a Certified Public Accountant and graduated from The State University of New York at Geneseo.

What is Thomas A. Szlosek's net worth?: The estimated net worth of Thomas A. Szlosek is at least $265,372.24 as of September 15th, 2023. Mr. Szlosek owns 13,034 shares of Avantor stock worth more than $265,372 as of November 22nd. This net worth estimate does not reflect any other assets that Mr. Szlosek may own. Learn More about Thomas A. Szlosek's net worth.
How do I contact Thomas A. Szlosek?: The corporate mailing address for Mr. Szlosek and other Avantor executives is BUILDING ONE SUITE 200 100 MATSONFORD ROAD, RADNOR PA, 19087. Avantor can also be reached via phone at (610) 386-1700 and via email at [email protected]. Learn More on Thomas A. Szlosek's contact information.
Has Thomas A. Szlosek been buying or selling shares of Avantor?: Thomas A. Szlosek has not been actively trading shares of Avantor over the course of the past ninety days. Most recently, on Wednesday, November 16th, Thomas A. Szlosek bought 12,500 shares of Avantor stock. The stock was acquired at an average cost of $20.71 per share, with a total value of $258,875.00. Following the completion of the transaction, the chief financial officer now directly owns 35,668 shares of the company's stock, valued at $738,684.28. Learn More on Thomas A. Szlosek's trading history.
Who are Avantor's active insiders?: Avantor's insider roster includes James Bramwell (EVP), Gerard Brophy (EVP), Christophe Couturier (EVP), Steven Eck (CAO), Rajiv Gupta (Director), Justin Miller (EVP), Jo Natauri (Director), Devashish Ohri (EVP), Christi Shaw (Director), Michael Stubblefield (CEO), Thomas Szlosek (CFO), Frederic Vanderhaegen (EVP), and Michael Wondrasch (EVP). Learn More on Avantor's active insiders.
Are insiders buying or selling shares of Avantor?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 9,728 shares worth more than $240,247.97. The most recent insider tranaction occured on September, 5th when CAO Steven W Eck sold 3,525 shares worth more than $88,336.50. Insiders at Avantor own 1.5% of the company. Learn More about insider trades at Avantor.
Information on this page was last updated on 9/5/2024.

Thomas A. Szlosek Insider Trading History at Avantor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2022	Buy	12,500	$20.71	$258,875.00	35,668

Thomas A. Szlosek Buying and Selling Activity at Avantor

Avantor Company Overview

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Today's Range

Now: $20.67

$20.25

$20.71

50 Day Range

MA: $24.01

$19.72

$27.70

2 Week Range

Now: $20.67

$19.59

$28.00

Volume

2,202,676 shs

Average Volume

6,478,650 shs

Market Capitalization

$14.07 billion

P/E Ratio

44.93

Dividend Yield

N/A

Beta

1.35

Financial Prophecy

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.